CVS Health Receives Price Target Increase from Truist; Stock Positioned as Blue Chip Buy Under $100
Truist Securities raised its price target on CVS Health to $108 from $102 on June 1, 2026, maintaining a "Buy" rating based on expected margin recovery and strong commercial business trends. The analyst cited favorable Q1 medical cost trends and embedded earnings potential in government businesses as key drivers. CVS also raised its full-year 2026 earnings guidance, with adjusted EPS expected between $6.24-$6.44 versus the prior range of $5.94-$6.14.
Truist Securities upgraded its outlook on CVS Health Corporation on June 1, 2026, raising its price target to $108 from $102 while maintaining a "Buy" rating. The analyst highlighted significant embedded earnings potential tied to ongoing margin recovery in the company's government businesses, alongside expectations for continued robust trends in the commercial segment. Supporting this thesis, CVS reported Q1 2026 total revenues of $100.4 billion (up 6.2% year-over-year) with adjusted EPS of $2.57, and medical cost trends that came in favorable to consensus expectations. In response to strong operational performance, CVS raised its full-year 2026 guidance, now projecting GAAP diluted EPS between $6.24-$6.44, up from the previous range of $5.94-$6.14. The stock's positioning under $100 per share makes it attractive as a blue-chip healthcare investment.
What different sources said
- Yahoo FinanceCenter
CVS Health (CVS): One of the Best Blue Chip Stocks Under $100 to Buy Now
Related
Asian stocks decline following US-Iran military escalation
Asian stock markets fell sharply after the US and Iran exchanged military strikes, with the US responding to Iran's downing of a US Army helicopter near the Strait of Hormuz. Oil prices initially dropped below $90 per barrel before partially recovering, while semiconductor stocks experienced significant intraday losses. The escalation has created uncertainty in energy markets and geopolitical risk despite current expectations that oil futures are not pricing in further escalation.
US Strategic Oil Reserves at Lowest Levels in Over 40 Years Amid Middle East Tensions
US strategic petroleum reserves have fallen to their lowest levels in more than four decades, according to analyst Rachel Ziemba. The decline comes as oil prices rise following military escalations between the US and Iran in the Persian Gulf, including an incident involving an American military helicopter near Oman. The reserve levels are significant for US energy security and could affect oil price stability during geopolitical crises.
SoftBank's $6 Billion OpenAI-Backed Margin Loan Stalls
SoftBank Group's efforts to secure a margin loan of at least $6 billion backed by its OpenAI stake have stalled after the company reduced its initial fundraising target from $10 billion. The Japanese conglomerate had already secured approximately $5 billion in commitments before discussions paused, though the reasons for the halt remain unclear. The development reflects shifting financing strategies as SoftBank explores alternative fundraising options.